29786-45-6

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(4-Methoxyphenyl)cyclobutanecarbonitrile is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs with unique therapeutic properties.
Used in Agrochemical Production:
1-(4-Methoxyphenyl)cyclobutanecarbonitrile is also utilized as an intermediate in the production of agrochemicals, playing a role in the development of new pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Synthesis:
1-(4-Methoxyphenyl)cyclobutanecarbonitrile is employed as a building block in organic synthesis, enabling the creation of more complex molecules with specific applications in various industries.
Used in Materials Science:
Due to its unique structure and reactivity, 1-(4-Methoxyphenyl)cyclobutanecarbonitrile is used in the field of materials science for the development of new materials with specialized properties.

Upstream product

• 104-47-2 p-methoxybenzylnitrile 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 29786-55-8 1-(4-methoxyphenyl)cyclobutane-1-carboxamide 
• 50921-37-4 1-(4-methoxy-phenyl)-cyclobutanecarboxylic acid 
• 39868-68-3 1-cyclobutyl-4-methoxybenzene 
• 405063-18-5 C₁₂H₁₄O₂ 
• 29786-28-5 (<1-(p-Methoxyphenyl)cyclobutyl>carbonyl)carbamsaeuremethylester 
• 29770-41-0 <<1-(p-Methoxyphenyl)cyclobutyl>carbonyl>harnstoff 
• 29786-34-3 (<1-(p-Methoxyphenyl)cyclobutyl>carbonyl)carbamsaeureethylester 
• 29770-28-3 <1-(p-Methoxyphenyl)-cyclobutyl>-carbonylisocyanat 
• 61492-43-1 (2S,5R,6R)-6-{[1-(4-Methoxy-phenyl)-cyclobutanecarbonyl]-amino}-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid 

Relevant academic research and scientific papers

Synthesis method of arylcyclobutane compound

The present invention discloses a method for synthesizing an arylcyclobutane compound to 1eq phenylacetonitrile and 1.1eq 1-bromo-3-chloropropane as raw material, N,N- dimethylacetamide as a solvent, plus 2.5eq sodium hydride, under the protection of iner

Iridium-Catalyzed Enantioselective C(sp3)–H Borylation of Cyclobutanes

We herein report the first example of iridium-catalyzed enantioselective C(sp3)–H borylation of cyclobutanes using benzoxazoline as the directing group. The combination of a chiral bidentate boryl ligand and an iridium precursor has found to effectively catalyze C(sp3)–H borylation to afford a variety of cyclobutylboronates with good to excellent enantioselectivities. We also demonstrate the synthetic utility of the current method by converting the stereogenic C—B bond to other functionalities.

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

Hydride Reduction by a Sodium Hydride-Iodide Composite

Sodium hydride (NaH) is widely used as a Br?nsted base in chemical synthesis and reacts with various Br?nsted acids, whereas it rarely behaves as a reducing reagent through delivery of the hydride to polar π electrophiles. This study presents a series of reduction reactions of nitriles, amides, and imines as enabled by NaH in the presence of LiI or NaI. This remarkably simple protocol endows NaH with unprecedented and unique hydride-donor chemical reactivity.

Phase transfer alkylation of arylacetonitriles revisited

Phase transfer alkylations of phenylacetonitrile derivatives carried out in the presence of 60-75% aqueous KOH, instead of the typical 50% NaOH, provide substantial improvements in the overall yields and purity of products. Reactions with simple secondary alkyl halides, as well as cycloalkylations with 1,2- and 1,3-dihaloalkanes proceed with good yields. Increasing the concentration of base diminishes the formation of by-products from competitive β-elimination processes.

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Thermal Decomposition of

A series of tert-butyl 1-arylcycloalkyl peresters was prepared, and the rate constants for the peresters' thermal decomposition were measured at several temperatures. The decomposition rates and aryl-substituent effects on the decomposition rates for the three series of peresters are remarkably similar to each other and to the acyclic α,α-dimethylbenzyl analogue previously investigated. The magnitude of the activation parameters for the rates of thermolysis of the alicyclic peresters and the solvent viscosity effects on these rates suggest that the 1-arylcyclobutyl (2), -cyclopentyl (3), and -cyclohexyl (4) peresters undergo thermal decomposition primarily by the concerted, two-bond-cleavage mechanism and that the 1-arylcyclopropyl peresters (1) undergo thermolysis primarily by the stepwise mechanism.